Gut Bacteria That Fight Depression: A Systematic Review of Psychobiotics

Depression affects approximately 280 million people worldwide and remains the leading cause of disability globally. Despite available treatments — including antidepressants, psychotherapy, and brain stimulation — more than 35% of patients are resistant to standard pharmacotherapy, and side effects remain a major barrier to adherence. This growing treatment gap has intensified interest in microbiome-targeted interventions, particularly psychobiotics: live microorganisms with demonstrated capacity to influence mental health through the gut-brain axis.

This PRISMA-compliant systematic review searched PubMed, Web of Science, and Scopus for publications from 2020 to 2024 using a structured algorithm combining terms for psychobiotics, metabolites, and mental health. From 369 initial records, 99 duplicates were removed, 154 were excluded at title/abstract screening, and 69 were excluded at full-text review, leaving 45 studies meeting all inclusion criteria. These spanned both human clinical trials and animal experimental models. Risk of bias was assessed using the Cochrane ROB 2 tool across five domains: randomization, deviation from interventions, missing data, outcome measurement, and selective reporting.

The most frequently studied psychobiotic genera were Lactobacillus (45.5%) and Bifidobacterium (29%), with notable representation from Akkermansia muciniphila. Strain sources were diverse: 24% from commercial preparations, 16% from human-derived isolates (gut, vaginal, and fecal microbiota), and 16% from food-derived sources such as fermented dairy and vegetables. Mechanistically, these bacteria exerted their antidepressant effects through four primary pathways: neurotransmitter regulation (27.1%), gut microbiota remodeling (27.1%), short-chain fatty acid production (16.9%), and modulation of inflammatory responses (15.3%). SCFAs — particularly butyrate, propionate, and acetate — cross the blood-brain barrier, influence vagal nerve signaling, and regulate HPA axis activity. GABA and serotonin produced by these strains directly modulate anxiety and mood circuitry. Indole derivatives, tryptophan metabolites produced by select Lactobacillus strains, further activate the aryl hydrocarbon receptor and regulate neuroinflammation.

Three strains emerged as particularly promising: Lactobacillus plantarum, Bifidobacterium breve, and Akkermansia muciniphila. These showed consistent effects across multiple models, reducing anxiety-like behaviors, lowering pro-inflammatory cytokines, normalizing corticosterone levels, and improving cognitive function. A VOSviewer keyword co-occurrence analysis revealed four thematic research clusters: preclinical neurobiological studies (centered on BDNF, GABA, and SCFAs), neurodegenerative disease models, clinical intervention trials, and a central integrative cluster anchored by major depressive disorder, gut dysbiosis, and serotonin — confirming the field's interdisciplinary convergence.

Clinically, the review highlights psychobiotics as viable adjunctive agents in depression management, potentially enabling lower doses of antidepressants and reducing side effect burden. Postbiotics — inactivated microbial cells and their metabolites — are also emerging as safer alternatives with easier storage and no infection risk. The authors note that formal meta-analysis was not possible due to high methodological heterogeneity across included studies, and that causal relationships between specific strains and clinical outcomes remain to be definitively established in large, well-controlled randomized trials.